Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BMRA 
Biomerica Inc (BMRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: BMRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -80.4% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.02M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) - | Beta 0.33 | 52 Weeks Range 1.93 - 8.80 | Updated Date 06/29/2025 |
52 Weeks Range 1.93 - 8.80 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -85.42% | Operating Margin (TTM) -108.13% |
Management Effectiveness
Return on Assets (TTM) -35.99% | Return on Equity (TTM) -72.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5377116 | Price to Sales(TTM) 1.41 |
Enterprise Value 5377116 | Price to Sales(TTM) 1.41 | ||
Enterprise Value to Revenue 0.95 | Enterprise Value to EBITDA -5.42 | Shares Outstanding 2545760 | Shares Floating 2384045 |
Shares Outstanding 2545760 | Shares Floating 2384045 | ||
Percent Insiders 10.13 | Percent Institutions 5.8 |
Upturn AI SWOT
Biomerica Inc
Company Overview
History and Background
Biomerica Inc. was founded in 1971. Initially focused on producing medical products for gastroenterology, the company has expanded its offerings to include diagnostics and therapeutic products for various gastrointestinal (GI) diseases. It has grown through product development and strategic acquisitions.
Core Business Areas
- Gastroenterology Diagnostics: Develops and commercializes diagnostic tests for gastrointestinal diseases, including Irritable Bowel Syndrome (IBS) and Helicobacter pylori (H. pylori) detection.
- Gastroenterology Therapeutics: Offers therapeutic products aimed at treating gastrointestinal disorders, focusing on conditions like ulcerative colitis and Crohn's disease.
Leadership and Structure
Zackary Irani serves as the Chairman, President, and CEO. The company operates with a functional organizational structure, emphasizing research and development, manufacturing, and sales & marketing.
Top Products and Market Share
Key Offerings
- InPouchu00ae HSV: A rapid test for Herpes Simplex Virus (HSV) detection. Competitors include Quidel Corporation and Abbott Laboratories. Data regarding market share is difficult to obtain from public domain and not available.
- hpylori test: A rapid test for Helicobacter pylori (H. pylori) detection in stool. Competitors include Abbott and Roche. Data regarding market share is difficult to obtain from public domain and not available.
- IBDifferentiateu00ae: A diagnostic test to differentiate between ulcerative colitis and Crohn's disease. Competitors in this space include Prometheus Laboratories (acquired by Nestle Health Science). Data regarding market share is difficult to obtain from public domain and not available.
Market Dynamics
Industry Overview
The diagnostics and therapeutics market for gastrointestinal diseases is growing due to increasing prevalence of GI disorders, aging populations, and advancements in diagnostic technologies.
Positioning
Biomerica Inc. is positioned as a specialist in the gastrointestinal health market, focusing on developing and commercializing innovative diagnostic and therapeutic solutions. They compete with larger, diversified healthcare companies.
Total Addressable Market (TAM)
The global gastrointestinal drugs market is projected to reach $61.4 billion by 2027. The diagnostics market is estimated at $9 billion. Biomerica is positioned to capture a portion of these markets through its specialized product offerings.
Upturn SWOT Analysis
Strengths
- Specialized focus on gastroenterology
- Proprietary diagnostic and therapeutic technologies
- Established distribution network
- Strong brand recognition in niche markets
Weaknesses
- Limited financial resources compared to larger competitors
- High dependence on a few key products
- Smaller sales and marketing team
- Potential competition from major pharmaceutical companies.
Opportunities
- Expansion into new geographic markets
- Development of novel diagnostic and therapeutic products
- Strategic partnerships with larger healthcare companies
- Increasing demand for non-invasive diagnostic tests
Threats
- Intense competition from established players
- Regulatory hurdles for new product approvals
- Changes in reimbursement policies
- Technological obsolescence
Competitors and Market Share
Key Competitors
- ABT
- ROCHE.SW
- DGX
Competitive Landscape
Biomerica competes with significantly larger companies. Its competitive advantage lies in its specialization and niche product offerings, but it faces challenges in terms of resources and scale.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require analysis of past financial statements from their SEC filings (e.g., 10-K reports).
Future Projections: Future growth projections are best found from investment analyst reports.
Recent Initiatives: Recent initiatives can be identified in press releases and investor presentations.
Summary
Biomerica Inc. is a niche player focused on gastroenterology diagnostics and therapeutics. While it has specialized expertise and established products, it faces competition from larger players. The company's growth depends on successful product development, strategic partnerships, and expansion into new markets, while guarding itself against competitive pressures and regulatory challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Biomerica Inc. SEC Filings (10-K, 10-Q), Company Website, Industry Reports, Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated based on industry reports and company presentations and may not be exact.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomerica Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2005-01-03 | CEO & Director Mr. Zackary S. Irani | ||
Sector Healthcare | Industry Medical Devices | Full time employees 64 | Website https://www.biomerica.com |
Full time employees 64 | Website https://www.biomerica.com | ||
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.